Table S1.

Heritability (%) of viability (%) at specific drug doses (μM) among different phenotypes

Phenotype	100 μM	33.3 μM	11.1 μM	3.7 μM	1.2 μM	0.4 μM	0.1 μM	0.05 μM	0.02 μM
B-cells exposed to selumetinib	58.3	47.6	43.5	47.9	51.7	41.6	35.2	30.6	27.5
B-cells exposed to BEZ-235	56.9	46.3	52	45	46.9	41.5	44	36.1	58.6
B-cells exposed to doxorubicin	73.5	79.2	87.8	83.4	78.8	70.6	58.2	38.1	38.9
B-cells exposed to idarubicin	35.2	45.4	60.7	85	69.3	51.1	49.5	36.2	51.5
T-cells exposed to selumetinib	53.2	47	46.7	43.5	51.5	54.4	50.7	44.5	50.9
T-cells exposed to BEZ-235	69.1	61.8	52	55.6	40.9	42.5	32	31.7	20.4
T-cells exposed to doxorubicin	89.3	86.8	85.8	81.6	77.9	79.2	81.6	75.8	63
T-cells exposed to idarubicin	44.5	42.7	83.6	90.6	87.5	72.5	45.3	37.8	22.8
Monocytes exposed to selumetinib	64.4	53.2	37.5	47	50.1	43.2	27.9	27.5	26.2
Monocytes exposed to BEZ-235	83.9	87.5	83.4	79.4	74.1	49.9	52.3	45	41.9
Monocytes exposed to doxorubicin	76.8	59.5	81.3	77.6	71.7	75.6	66.2	44.8	40.6
Monocytes exposed to idarubicin	58.6	47.9	80.5	75.1	73.6	74.9	55	46.8	32